BMS to Build $2.3B Manufacturing Campus in Houston

Editor’s Take: The selection of Houston marks a significant milestone in BMS’ $40 billion commitment to invest in the United States over five years across research and development, technology and domestic manufacturing.

Bristol Myers Squibb has selected Houston, Texas, as the site for a new multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients.

The campus, at Generation Park in Houston, will create nearly 500 skilled jobs and is designed to grow in scale, capability and workforce for decades to come.

Modular and Multi-Modal Design

The Houston site’s modular design will allow BMS to add and reconfigure manufacturing capacity as needed, reflecting BMS’ current and future pipeline. Its multi-modal capabilities will allow BMS to manufacture multiple types of medicines—such as small molecules, biologics, and antibody-drug conjugates—across a range of disease areas, supporting drug product and finished goods manufacturing from late development through launch. This flexibility aims to ensure the campus can evolve to meet patient needs well into the future.

“This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation,” said Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb. “As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life.”

Related Insights

Learn about big pharma’s investments in the U.S.